Deuterated compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-11845722-B2
Application number	US-202217929505-A
Country	US
Kind code	B2
Filing date	Sep 2, 2022
Priority date	Aug 21, 2015
Publication date	Dec 19, 2023
Grant date	Dec 19, 2023

Abstract

The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

First claim

We claim:

1. A method of treating a disease, disorder, or condition in which aldehyde toxicity is implicated in a subject in need thereof, comprising administering topically or systemically to the subject a compound of Formula II-A or II-B:

or a pharmaceutically acceptable salt thereof, wherein:
R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
R 2 is selected from hydrogen or deuterium;
R 3 is —CD 3 ;
R 4 is —CD 3 ; and
R 5 , R 6 , R 7 , and R 8 are each independently selected from hydrogen or deuterium.

2. The method of claim 1 , wherein at least one of R 2 , R 5 , R 6 , R 7 , or R 8 is deuterium.

3. The method of claim 1 , wherein the compound is of Formula II-A, or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 , wherein at least one of R 2 , R 5 , R 6 , R 7 , or R 8 is deuterium.

5. The method of claim 1 , wherein each of R 5 , R 6 , R 7 , and R 8 is as defined in an entry set forth in the table below:

TABLE 1c

Entry
R 5
R 6
R 7
R 8

i
H
H
H
H

ii
H
H
H
D

iii
H
H
D
H

iv
H
D
H
H

v
D
H
H
H

vi
H
H
D
D

vii
H
D
H
D

viii
D
H
H
D

ix
H
D
D
H

x
D
H
D
H

xi
D
D
H
H

xii
H
D
D
D

xiii
D
H
D
D

xiv
D
D
H
D

xv
D
D
D
H

xvi
D
D
D
D

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the compound is of the following structure:

or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 50% or greater.

8. The method of claim 1 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of 90% or greater.

9. The method of claim 6 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 50% or greater.

10. The method of claim 6 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 90% or greater.

11. The method of claim 6 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of 95% or greater.

12. The method of claim 1 , wherein the disease, disorder, or condition is an ocular disorder.

13. The method of claim 12 , wherein the ocular disorder is macular degeneration or Stargardt disease.

14. The method of claim 12 , wherein the ocular disorder is selected from the group consisting of dry eye syndrome, cataracts, keratoconus, bullous and other keratopathy, Fuch's endothelial dystrophy, allergic conjunctivitis, ocular cicatricial pemphigoid, conditions associated with PRK healing and other corneal healing, conditions associated with tear lipid degradation or lacrimal gland dysfunction, uveitis, scleritis, ocular Stevens Johnson Syndrome, and ocular rosacea.

15. The method of claim 14 , wherein the ocular disorder is dry eye syndrome.

16. The method of claim 14 , wherein the ocular disorder is selected from the group consisting of uveitis, scleritis, ocular Stevens Johnson Syndrome, and ocular rosacea.

17. The method of claim 14 , wherein the ocular disorder is ocular rosacea or uveitis.

18. The method of claim 1 , wherein the disease, disorder, or condition is a skin disease, disorder, or condition selected from the group consisting of psoriasis, topical (discoid) lupus, contact dermatitis, atopic dermatitis, allergic dermatitis, radiation dermatitis, acne vulgaris, and Sjogren-Larsson Syndrome and other ichthyoses.

19. The method of claim 18 , wherein the skin disease, disorder, or condition is contact dermatitis, atopic dermatitis, allergic dermatitis, or radiation dermatitis.

20. The method of claim 18 , wherein the skin disease, disorder, or condition is Sjogren-Larsson Syndrome.

21. The method of claim 9 , wherein the disease, disorder, or condition is an autoimmune, immune-mediated, inflammatory, cardiovascular, or neurological disease, or diabetes, metabolic syndrome, or a fibrotic disease.

22. The method of claim 1 , wherein the disease, disorder, or condition is selected from the group consisting of lupus, scleroderma, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, inflammatory bowel disease, sepsis, atherosclerosis, ischemic-reperfusion injury, Parkinson's disease, Alzheimer's disease, succinic semialdehyde dehydrogenase deficiency, multiple sclerosis, and amyotrophic lateral sclerosis.

Assignees

• Aldeyra Therapeutics Inc

Inventors

• Brady Todd
• Young Scott
• Kinney William A
• Macdonald Susan

Classifications

• C07B2200/05

  Isotopically modified compounds, e.g. labelled · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title